 Jody Tanabe
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 18 | 2019 | 947 | 3.650 |
Why?
| | Magnetic Resonance Imaging | 54 | 2024 | 3039 | 3.220 |
Why?
| | Brain | 33 | 2024 | 2371 | 2.490 |
Why?
| | Brain Mapping | 19 | 2024 | 524 | 1.920 |
Why?
| | Nerve Net | 7 | 2019 | 226 | 1.750 |
Why?
| | Cerebrovascular Circulation | 7 | 2022 | 221 | 1.740 |
Why?
| | Cerebral Cortex | 13 | 2019 | 380 | 1.670 |
Why?
| | Prefrontal Cortex | 6 | 2017 | 262 | 1.500 |
Why?
| | Decision Making | 9 | 2017 | 782 | 1.470 |
Why?
| | Acetates | 2 | 2021 | 95 | 1.350 |
Why?
| | Impulsive Behavior | 7 | 2015 | 113 | 1.340 |
Why?
| | Image Processing, Computer-Assisted | 21 | 2019 | 682 | 1.270 |
Why?
| | Frontal Lobe | 7 | 2015 | 141 | 1.220 |
Why?
| | Gambling | 5 | 2015 | 31 | 1.080 |
Why?
| | Thalamus | 4 | 2021 | 74 | 1.040 |
Why?
| | Neuroimaging | 6 | 2021 | 249 | 1.040 |
Why?
| | Nicotine | 6 | 2013 | 265 | 0.990 |
Why?
| | Limbic System | 4 | 2015 | 43 | 0.960 |
Why?
| | Psychotic Disorders | 2 | 2024 | 118 | 0.890 |
Why?
| | Behavior | 3 | 2021 | 92 | 0.880 |
Why?
| | Risk-Taking | 3 | 2015 | 333 | 0.880 |
Why?
| | Nicotinic Agonists | 5 | 2011 | 100 | 0.810 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2019 | 159 | 0.800 |
Why?
| | Learning | 2 | 2019 | 350 | 0.790 |
Why?
| | Sex Characteristics | 4 | 2020 | 640 | 0.790 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 70 | 0.750 |
Why?
| | Reward | 3 | 2023 | 211 | 0.730 |
Why?
| | Neostriatum | 2 | 2014 | 29 | 0.730 |
Why?
| | Neuropsychiatry | 1 | 2020 | 15 | 0.720 |
Why?
| | Psychomotor Performance | 5 | 2017 | 280 | 0.720 |
Why?
| | Alcoholism | 4 | 2021 | 713 | 0.690 |
Why?
| | Neural Pathways | 5 | 2017 | 261 | 0.650 |
Why?
| | Craving | 1 | 2019 | 32 | 0.650 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 44 | 0.640 |
Why?
| | Central Nervous System Depressants | 1 | 2019 | 81 | 0.640 |
Why?
| | Schizophrenia | 7 | 2023 | 414 | 0.620 |
Why?
| | Drug Users | 2 | 2016 | 41 | 0.600 |
Why?
| | Gray Matter | 2 | 2015 | 67 | 0.600 |
Why?
| | Parkinson Disease | 3 | 2017 | 345 | 0.600 |
Why?
| | Adult | 38 | 2024 | 30528 | 0.580 |
Why?
| | Levodopa | 1 | 2017 | 23 | 0.570 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 26 | 0.560 |
Why?
| | Male | 54 | 2022 | 55555 | 0.560 |
Why?
| | Sensation Disorders | 1 | 2017 | 31 | 0.550 |
Why?
| | Tobacco Use Disorder | 1 | 2019 | 234 | 0.550 |
Why?
| | Neuropsychological Tests | 9 | 2016 | 927 | 0.550 |
Why?
| | Sexism | 1 | 2017 | 44 | 0.540 |
Why?
| | Female | 54 | 2022 | 59466 | 0.530 |
Why?
| | Pursuit, Smooth | 3 | 2005 | 16 | 0.520 |
Why?
| | Humans | 69 | 2024 | 114624 | 0.510 |
Why?
| | Ethanol | 1 | 2019 | 538 | 0.490 |
Why?
| | Functional Laterality | 3 | 2013 | 198 | 0.490 |
Why?
| | Ventral Striatum | 1 | 2015 | 8 | 0.490 |
Why?
| | Cognition | 2 | 2019 | 988 | 0.450 |
Why?
| | Cytokines | 1 | 2021 | 1840 | 0.440 |
Why?
| | Hippocampus | 7 | 2015 | 693 | 0.430 |
Why?
| | Attention | 3 | 2005 | 393 | 0.430 |
Why?
| | Magnetic Resonance Angiography | 2 | 2009 | 219 | 0.430 |
Why?
| | Patient Selection | 1 | 2017 | 641 | 0.430 |
Why?
| | Conduct Disorder | 4 | 2017 | 193 | 0.410 |
Why?
| | Gyrus Cinguli | 4 | 2012 | 70 | 0.380 |
Why?
| | Healthcare Disparities | 1 | 2017 | 479 | 0.380 |
Why?
| | Inflammation | 1 | 2021 | 2478 | 0.360 |
Why?
| | Veins | 1 | 2009 | 55 | 0.320 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 4 | 2015 | 230 | 0.320 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2008 | 20 | 0.310 |
Why?
| | Executive Function | 1 | 2013 | 379 | 0.310 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 38 | 0.310 |
Why?
| | Reaction Time | 3 | 2013 | 376 | 0.300 |
Why?
| | Cues | 4 | 2019 | 300 | 0.290 |
Why?
| | Analysis of Variance | 4 | 2013 | 1226 | 0.280 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2020 | 83 | 0.270 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 10 | 0.260 |
Why?
| | Pilot Projects | 2 | 2021 | 1372 | 0.250 |
Why?
| | Dementia, Vascular | 3 | 2000 | 16 | 0.250 |
Why?
| | Evoked Potentials | 1 | 2005 | 108 | 0.240 |
Why?
| | Middle Aged | 16 | 2021 | 26719 | 0.240 |
Why?
| | Delay Discounting | 1 | 2023 | 16 | 0.220 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2003 | 19 | 0.220 |
Why?
| | Case-Control Studies | 5 | 2016 | 3003 | 0.220 |
Why?
| | Interview, Psychological | 2 | 2013 | 86 | 0.210 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 2002 | 2 | 0.210 |
Why?
| | Herpesvirus 1, Human | 1 | 2003 | 76 | 0.210 |
Why?
| | Thoracic Vertebrae | 1 | 2002 | 68 | 0.200 |
Why?
| | Adolescent Development | 2 | 2021 | 83 | 0.200 |
Why?
| | Multimodal Imaging | 2 | 2019 | 88 | 0.200 |
Why?
| | Administration, Oral | 2 | 2019 | 728 | 0.200 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 10 | 0.190 |
Why?
| | Feedback, Psychological | 2 | 2013 | 20 | 0.190 |
Why?
| | Amphetamine-Related Disorders | 2 | 2012 | 28 | 0.180 |
Why?
| | Oxygen | 4 | 2017 | 854 | 0.180 |
Why?
| | Random Allocation | 1 | 2021 | 335 | 0.170 |
Why?
| | Benzylidene Compounds | 2 | 2010 | 17 | 0.170 |
Why?
| | Fingers | 2 | 2013 | 83 | 0.170 |
Why?
| | Epilepsy | 1 | 2024 | 277 | 0.170 |
Why?
| | Young Adult | 5 | 2019 | 10455 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 482 | 0.170 |
Why?
| | Tremor | 2 | 2017 | 45 | 0.170 |
Why?
| | Cocaine-Related Disorders | 2 | 2012 | 107 | 0.170 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2019 | 17 | 0.160 |
Why?
| | Reference Values | 4 | 2021 | 742 | 0.160 |
Why?
| | Administration, Intravenous | 1 | 2019 | 124 | 0.160 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 60 | 0.150 |
Why?
| | Smoking | 3 | 2012 | 1380 | 0.150 |
Why?
| | Alzheimer Disease | 3 | 1998 | 442 | 0.150 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 259 | 0.150 |
Why?
| | Cross-Over Studies | 4 | 2013 | 440 | 0.150 |
Why?
| | Selection Bias | 1 | 2017 | 33 | 0.140 |
Why?
| | Artifacts | 3 | 2009 | 113 | 0.140 |
Why?
| | Pyridines | 2 | 2010 | 425 | 0.140 |
Why?
| | Spinal Cord | 1 | 1998 | 347 | 0.130 |
Why?
| | DiGeorge Syndrome | 1 | 2016 | 18 | 0.130 |
Why?
| | Brain Neoplasms | 1 | 2024 | 979 | 0.130 |
Why?
| | Mental Disorders | 1 | 2023 | 892 | 0.130 |
Why?
| | Photic Stimulation | 4 | 2017 | 203 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 2 | 2009 | 510 | 0.120 |
Why?
| | Organ Size | 3 | 2015 | 434 | 0.120 |
Why?
| | Cerebellum | 2 | 2013 | 200 | 0.120 |
Why?
| | Postural Balance | 1 | 2017 | 183 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2021 | 2387 | 0.120 |
Why?
| | Problem Behavior | 1 | 2015 | 86 | 0.110 |
Why?
| | Age Factors | 1 | 2021 | 2894 | 0.110 |
Why?
| | Single-Blind Method | 2 | 2012 | 258 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2013 | 4620 | 0.110 |
Why?
| | Alcohol Drinking | 1 | 2019 | 651 | 0.110 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 124 | 0.110 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2013 | 35 | 0.110 |
Why?
| | Aged | 11 | 2017 | 19061 | 0.110 |
Why?
| | Personality Inventory | 1 | 2013 | 131 | 0.100 |
Why?
| | Heroin Dependence | 1 | 2012 | 22 | 0.100 |
Why?
| | Principal Component Analysis | 1 | 2013 | 175 | 0.100 |
Why?
| | Brain Ischemia | 3 | 2000 | 299 | 0.100 |
Why?
| | Emotions | 1 | 2017 | 472 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2017 | 489 | 0.100 |
Why?
| | Adolescent | 9 | 2023 | 17831 | 0.100 |
Why?
| | Efficiency | 1 | 2012 | 84 | 0.100 |
Why?
| | Cognition Disorders | 2 | 2010 | 476 | 0.100 |
Why?
| | Appetite Regulation | 1 | 2011 | 26 | 0.090 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 928 | 0.090 |
Why?
| | Fatal Outcome | 2 | 2019 | 284 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1448 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 64 | 0.090 |
Why?
| | Regression Analysis | 1 | 2013 | 944 | 0.090 |
Why?
| | Inpatients | 1 | 2014 | 380 | 0.090 |
Why?
| | Cerebrospinal Fluid | 2 | 2003 | 90 | 0.090 |
Why?
| | Sex Factors | 1 | 2015 | 1715 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1077 | 0.090 |
Why?
| | Visual Perception | 1 | 2011 | 139 | 0.080 |
Why?
| | Disease Progression | 2 | 2008 | 2380 | 0.080 |
Why?
| | Atrophy | 5 | 2007 | 152 | 0.080 |
Why?
| | Nutritional Status | 1 | 2011 | 287 | 0.080 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2008 | 9 | 0.080 |
Why?
| | Temperance | 1 | 2008 | 13 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2000 | 473 | 0.080 |
Why?
| | Energy Intake | 1 | 2011 | 427 | 0.080 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 274 | 0.080 |
Why?
| | Wechsler Scales | 1 | 2007 | 52 | 0.070 |
Why?
| | Chewing Gum | 1 | 2007 | 8 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2007 | 82 | 0.070 |
Why?
| | Alcohols | 1 | 2007 | 28 | 0.070 |
Why?
| | Alcohol-Related Disorders | 1 | 2008 | 113 | 0.070 |
Why?
| | Parietal Lobe | 2 | 2005 | 41 | 0.070 |
Why?
| | Normal Distribution | 1 | 2006 | 19 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1342 | 0.070 |
Why?
| | Models, Neurological | 1 | 2007 | 212 | 0.060 |
Why?
| | Dissociative Disorders | 1 | 2005 | 21 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2009 | 1660 | 0.060 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 28 | 0.060 |
Why?
| | Aged, 80 and over | 5 | 1999 | 6344 | 0.060 |
Why?
| | Taste | 1 | 2007 | 208 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 42 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 843 | 0.060 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 120 | 0.060 |
Why?
| | Event-Related Potentials, P300 | 1 | 2004 | 12 | 0.060 |
Why?
| | Aspartic Acid | 3 | 2000 | 77 | 0.060 |
Why?
| | Ocular Motility Disorders | 1 | 2004 | 25 | 0.060 |
Why?
| | Child | 4 | 2024 | 18404 | 0.060 |
Why?
| | Aphasia | 1 | 2003 | 19 | 0.060 |
Why?
| | Psychopathology | 1 | 2023 | 45 | 0.050 |
Why?
| | Heart Rate | 1 | 2007 | 709 | 0.050 |
Why?
| | Temporal Lobe | 1 | 2003 | 79 | 0.050 |
Why?
| | Pattern Recognition, Visual | 1 | 2004 | 86 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2014 | 9084 | 0.050 |
Why?
| | Acetazolamide | 1 | 2022 | 30 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2002 | 39 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2005 | 41 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2002 | 93 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2279 | 0.050 |
Why?
| | Motor Activity | 1 | 2006 | 640 | 0.050 |
Why?
| | Electroencephalography | 1 | 2003 | 362 | 0.050 |
Why?
| | Stroke | 2 | 2019 | 1021 | 0.050 |
Why?
| | Language | 1 | 2024 | 262 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2004 | 225 | 0.050 |
Why?
| | Liver Diseases | 1 | 2003 | 255 | 0.050 |
Why?
| | Incidental Findings | 1 | 2021 | 70 | 0.050 |
Why?
| | Blood Pressure | 1 | 2007 | 1538 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 993 | 0.050 |
Why?
| | Seizures | 1 | 2003 | 340 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2005 | 376 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1466 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2019 | 12 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2019 | 30 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 1999 | 39 | 0.040 |
Why?
| | Coloring Agents | 1 | 2019 | 72 | 0.040 |
Why?
| | Obesity | 1 | 2011 | 2507 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 54 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2019 | 133 | 0.040 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 489 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 130 | 0.040 |
Why?
| | Animals | 1 | 2019 | 31695 | 0.040 |
Why?
| | Brain Chemistry | 1 | 1998 | 115 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 387 | 0.040 |
Why?
| | Critical Illness | 1 | 2022 | 644 | 0.040 |
Why?
| | Visual Acuity | 1 | 2019 | 274 | 0.040 |
Why?
| | Cerebral Ventricles | 1 | 1997 | 47 | 0.030 |
Why?
| | Motor Neurons | 1 | 1998 | 212 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 632 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 1842 | 0.030 |
Why?
| | Empathy | 1 | 2017 | 138 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 41 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 445 | 0.030 |
Why?
| | Glucose | 1 | 1999 | 896 | 0.030 |
Why?
| | Hyperphagia | 1 | 2011 | 28 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 4894 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6217 | 0.020 |
Why?
| | Sensation | 1 | 2011 | 44 | 0.020 |
Why?
| | Labor, Induced | 1 | 2011 | 32 | 0.020 |
Why?
| | Thinness | 1 | 2011 | 87 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2011 | 217 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 150 | 0.020 |
Why?
| | Eye Movements | 1 | 2010 | 53 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 122 | 0.020 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2010 | 96 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 240 | 0.020 |
Why?
| | Food | 1 | 2011 | 160 | 0.020 |
Why?
| | Hemodynamics | 1 | 2013 | 1012 | 0.020 |
Why?
| | Creatine | 2 | 2000 | 50 | 0.020 |
Why?
| | Aspirin | 1 | 2011 | 324 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 951 | 0.020 |
Why?
| | Dominance, Cerebral | 1 | 2007 | 50 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 497 | 0.020 |
Why?
| | Nerve Fibers | 1 | 2007 | 87 | 0.020 |
Why?
| | Weight Loss | 1 | 2011 | 641 | 0.020 |
Why?
| | Cranial Nerves | 1 | 2005 | 11 | 0.020 |
Why?
| | Sural Nerve | 1 | 2005 | 19 | 0.020 |
Why?
| | Genotype | 1 | 2010 | 1760 | 0.020 |
Why?
| | Graves Disease | 1 | 2005 | 32 | 0.020 |
Why?
| | Hypertrophy | 1 | 2005 | 109 | 0.020 |
Why?
| | Visual Pathways | 1 | 2005 | 44 | 0.020 |
Why?
| | Schizophrenic Psychology | 1 | 2005 | 86 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 274 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 331 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2005 | 294 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 320 | 0.010 |
Why?
| | Visual Fields | 1 | 2004 | 77 | 0.010 |
Why?
| | Myelin Sheath | 1 | 2005 | 144 | 0.010 |
Why?
| | Early Diagnosis | 1 | 2005 | 217 | 0.010 |
Why?
| | Axons | 1 | 2005 | 177 | 0.010 |
Why?
| | Gene Frequency | 1 | 2005 | 477 | 0.010 |
Why?
| | Head | 1 | 2004 | 85 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 1879 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2004 | 140 | 0.010 |
Why?
| | Movement | 1 | 2004 | 244 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 646 | 0.010 |
Why?
| | Risk | 1 | 2004 | 812 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1999 | 58 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 5517 | 0.010 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 76 | 0.010 |
Why?
| | Protons | 1 | 1997 | 73 | 0.010 |
Why?
| | Choline | 1 | 1998 | 106 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2004 | 2084 | 0.010 |
Why?
| | Biomarkers | 1 | 2005 | 3408 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2537 | 0.010 |
Why?
|
|
Tanabe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|